Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation. Issue 10 (October 2022)

• Record Type: Journal Article
• Authors: Kumar, Dhiraj; Md Ashraf, Ghulam; Bilgrami, Anwar L.; Imtaiyaz Hassan, Md
• Is Part Of: Drug discovery today. Volume 27:Issue 10(2022)
• Publication Date: 2022-10
• Subjects: Clinical products -- Drug discovery -- Emerging technologies -- Neurodegenerative disease -- Pharmaceutical development -- Targeted therapy; NDD Neurodegenerative diseases -- AD Alzheimer's disease -- PD Parkinson's disease -- SCP Stem-cell-based product -- iPSC Induced pluripotent stem cells -- MSC Mesenchymal stem cells -- TUBEs Tandem ubiquitin-binding entities -- PROTACs Proteolysis targeting chimerics -- SNIPERs Specific and non-genetic IAP-dependent protein erasers -- CLIPTACs Click-formed proteolysis targeting chimeras; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2022.06.005
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: Rivastigmine, Levo/Carbi-dopa, Tetrabenazine, and Arimoclomol are leading therapeutics for neurodegenerative diseases. These drugs have intriguing therapeutic efficacy in clinical trials, with unprecedented endpoints. Roche gained top stats (US$338.7 billion) with many investigational and clinical products. Stem cell therapy and targeted protein degraders are studied in the greatest numbers of clinical investigations. Antibodies are promising future therapies for neurodegenerative diseases. Abstract : Despite a century of intensive research, there is still a lack of disease-modifying treatments for neurodegenerative diseases that pose a threat to human society. A well-documented knowledge and resource gap has impeded the translation of fundamental research into promising therapies. In addition, the analysis of extensive preclinical data to allow the improved selection of therapeutic technologies and clinical candidates for further development is challenging. To address this need, we describe technologies that have emerged over the past decade that have enabled the development of novel, high-quality, cost-effective treatments for major neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Moreover, we benchmark emerging technologies that have been adopted by top pharmaceutical companies looking to bridge the gap between drug discovery and drug development in neurodegenerative disease.